Log in
NYSE:DVA

DaVita Competitors

$89.71
-1.34 (-1.47 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$89.22
Now: $89.71
$90.82
50-Day Range
$81.56
MA: $87.34
$91.84
52-Week Range
$57.75
Now: $89.71
$92.67
Volume665,077 shs
Average Volume1.26 million shs
Market Capitalization$10.94 billion
P/E Ratio14.15
Dividend YieldN/A
Beta1.18

Competitors

DaVita (NYSE:DVA) Vs. LH, DGX, AMED, CHE, LHCG, and AMN

Should you be buying DVA stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to DaVita, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), and AMN Healthcare Services (AMN).

Laboratory Co. of America (NYSE:LH) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

88.7% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 91.6% of DaVita shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Laboratory Co. of America and DaVita, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011502.94
DaVita05202.29

Laboratory Co. of America currently has a consensus price target of $218.4706, indicating a potential upside of 8.18%. DaVita has a consensus price target of $77.50, indicating a potential downside of 13.61%. Given Laboratory Co. of America's stronger consensus rating and higher possible upside, equities research analysts plainly believe Laboratory Co. of America is more favorable than DaVita.

Valuation & Earnings

This table compares Laboratory Co. of America and DaVita's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion1.70$823.80 million$11.3217.84
DaVita$11.39 billion0.96$810.98 million$5.4016.61

Laboratory Co. of America has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Laboratory Co. of America and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America3.16%14.39%5.91%
DaVita7.20%40.78%5.29%

Risk and Volatility

Laboratory Co. of America has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Summary

Laboratory Co. of America beats DaVita on 10 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Quest Diagnostics and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics9.99%13.78%6.33%
DaVita7.20%40.78%5.29%

Earnings and Valuation

This table compares Quest Diagnostics and DaVita's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.16$858 million$6.5618.95
DaVita$11.39 billion0.96$810.98 million$5.4016.61

Quest Diagnostics has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Quest Diagnostics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Quest Diagnostics and DaVita, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09902.50
DaVita05202.29

Quest Diagnostics presently has a consensus price target of $127.50, suggesting a potential upside of 2.56%. DaVita has a consensus price target of $77.50, suggesting a potential downside of 13.61%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe Quest Diagnostics is more favorable than DaVita.

Insider and Institutional Ownership

87.2% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 91.6% of DaVita shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 1.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Quest Diagnostics beats DaVita on 11 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Insider and Institutional Ownership

89.7% of Amedisys shares are owned by institutional investors. Comparatively, 91.6% of DaVita shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 1.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amedisys and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys6.50%22.41%10.67%
DaVita7.20%40.78%5.29%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Amedisys and DaVita, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys031102.79
DaVita05202.29

Amedisys presently has a consensus price target of $239.4286, suggesting a potential downside of 5.26%. DaVita has a consensus price target of $77.50, suggesting a potential downside of 13.61%. Given Amedisys' stronger consensus rating and higher possible upside, research analysts plainly believe Amedisys is more favorable than DaVita.

Risk & Volatility

Amedisys has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Earnings and Valuation

This table compares Amedisys and DaVita's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.20$126.83 million$4.4057.44
DaVita$11.39 billion0.96$810.98 million$5.4016.61

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares DaVita and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion0.96$810.98 million$5.4016.61
Chemed$1.94 billion4.04$219.92 million$13.9535.30

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DaVita and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.20%40.78%5.29%
Chemed12.99%36.71%20.52%

Insider & Institutional Ownership

91.6% of DaVita shares are owned by institutional investors. Comparatively, 90.6% of Chemed shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Comparatively, 4.0% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

DaVita has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for DaVita and Chemed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita05202.29
Chemed00303.00

DaVita currently has a consensus target price of $77.50, suggesting a potential downside of 13.61%. Chemed has a consensus target price of $520.00, suggesting a potential upside of 5.60%. Given Chemed's stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than DaVita.

Summary

Chemed beats DaVita on 9 of the 14 factors compared between the two stocks.

LHC Group (NASDAQ:LHCG) and DaVita (NYSE:DVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for LHC Group and DaVita, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LHC Group02702.78
DaVita05202.29

LHC Group currently has a consensus target price of $198.1250, suggesting a potential downside of 10.19%. DaVita has a consensus target price of $77.50, suggesting a potential downside of 13.61%. Given LHC Group's stronger consensus rating and higher possible upside, analysts plainly believe LHC Group is more favorable than DaVita.

Earnings & Valuation

This table compares LHC Group and DaVita's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LHC Group$2.08 billion3.35$95.73 million$4.4749.35
DaVita$11.39 billion0.96$810.98 million$5.4016.61

DaVita has higher revenue and earnings than LHC Group. DaVita is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

LHC Group has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares LHC Group and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LHC Group5.76%9.08%6.24%
DaVita7.20%40.78%5.29%

Insider and Institutional Ownership

91.6% of DaVita shares are held by institutional investors. 4.8% of LHC Group shares are held by company insiders. Comparatively, 1.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AMN Healthcare Services (NYSE:AMN) and DaVita (NYSE:DVA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

99.0% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 91.6% of DaVita shares are held by institutional investors. 1.4% of AMN Healthcare Services shares are held by insiders. Comparatively, 1.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares AMN Healthcare Services and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AMN Healthcare Services3.65%21.06%7.25%
DaVita7.20%40.78%5.29%

Volatility and Risk

AMN Healthcare Services has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Earnings and Valuation

This table compares AMN Healthcare Services and DaVita's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.22 billion1.41$113.99 million$3.1820.98
DaVita$11.39 billion0.96$810.98 million$5.4016.61

DaVita has higher revenue and earnings than AMN Healthcare Services. DaVita is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AMN Healthcare Services and DaVita, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AMN Healthcare Services00713.13
DaVita05202.29

AMN Healthcare Services currently has a consensus price target of $68.2857, suggesting a potential upside of 2.33%. DaVita has a consensus price target of $77.50, suggesting a potential downside of 13.61%. Given AMN Healthcare Services' stronger consensus rating and higher probable upside, equities research analysts clearly believe AMN Healthcare Services is more favorable than DaVita.

Summary

AMN Healthcare Services beats DaVita on 9 of the 15 factors compared between the two stocks.


DaVita Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.3$201.96-2.7%$19.67 billion$11.55 billion55.03
Quest Diagnostics logo
DGX
Quest Diagnostics
1.8$124.32-2.3%$16.70 billion$7.73 billion22.56Earnings Announcement
Analyst Report
Analyst Revision
Amedisys logo
AMED
Amedisys
1.3$252.72-0.6%$8.15 billion$1.96 billion65.47Upcoming Earnings
Chemed logo
CHE
Chemed
1.4$492.41-0.8%$7.78 billion$1.94 billion30.95Upcoming Earnings
LHC Group logo
LHCG
LHC Group
1.0$220.60-1.7%$6.97 billion$2.08 billion58.21Analyst Downgrade
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.2$66.73-0.3%$3.13 billion$2.22 billion36.87
R1 RCM logo
RCM
R1 RCM
1.3$17.11-2.1%$1.98 billion$1.19 billion171.12Upcoming Earnings
The Providence Service logo
PRSC
The Providence Service
0.8$119.09-0.4%$1.67 billion$1.51 billion-1,984.50
CorVel logo
CRVL
CorVel
1.0$91.89-0.3%$1.65 billion$592.22 million40.13Upcoming Earnings
MEDNAX logo
MD
MEDNAX
1.5$13.90-5.3%$1.19 billion$3.51 billion-0.59
Tivity Health logo
TVTY
Tivity Health
1.4$14.59-0.2%$708.49 million$1.13 billion-1.47
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.9$7.39-3.5%$287.38 million$822.22 million-12.96
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.6$3.69-10.6%$14.92 million$24.08 million-0.44Analyst Revision
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.